TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL
Panelists discuss the efficacy and safety of chimeric antigen receptor T-cell (CAR T) therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and compare the data collected from the TRANSFORM and ZUMA-7 trials, including information regarding the patient control group, patient population prior response, crossovers of both trials, and vein-to-vein time.
Tailoring Therapy: Patient-Specific Decision-Making in Relapsed DLBCL
Panelists discuss the optimal timing of chimeric antigen receptor T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), which requires careful evaluation of patient fitness, disease burden, prior treatment response, and logistical factors. Key considerations include performance status, comorbidities, disease aggressiveness, and the availability of bridging therapy. Treatment decisions should be individualized based on patient-specific risk factors, prior therapy outcomes, and care goals while balancing the potential benefits and risks across different lines of treatment.
Beyond Salvage: When to Move to CAR T in Relapsed DLBCL
Panelists discuss, when evaluating chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), how key considerations include the patient’s fitness, disease burden, prior treatment response, and timing of referral. The limitations of traditional salvage therapy, with historically poor outcomes, must be weighed against CAR T’s potential for durable remissions despite its risks and complexities.
DLBCL in Focus: Transforming Outcomes With CAR T Therapy
Panelists discuss how the diffuse large B-cell lymphoma (DLBCL) treatment landscape has seen significant evolution with the integration of targeted therapies and chimeric antigen receptor T-cell treatments, supplementing traditional R-CHOP. However, early relapsed/refractory cases remain challenging due to complex tumor biology and resistance mechanisms. This underscores the need for better up-front risk stratification tools and biomarker-driven treatment selection.